The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Open accessAbstract
To design clinical trials for the frontotemporal lobar degenerations (FTLD), knowledge about measurement of disease progression is needed to estimate power and enable the choice of optimal outcome measures. The aim here was to conduct a multicentre, 1 year replica of a clinical trial in patients with one of four FTLD syndromes, behavioural variant frontotemporal dementia (bvFTD), progressive nonfluent aphasia (PNFA), progressive logopenic aphasia (PLA) and semantic dementia (SMD). Patients with one of the four FTLD syndromes were recruited from five academic medical centres over a 2 year period. Standard operationalized diagnostic criteria were used. In addition to clinical inclusion and exclusion criteria, patients were required to exhibit focal frontal, temporal or insular brain atrophy or dysfunction by neuroimaging. Patients underwent neuropsychological, functional, behavioural, neurological and MR imaging assessment at baseline and approximately 12 months later. Potential outcome measures were examined for their rates of floor and ceiling values at baseline and end of study, their mean changes and variances. The neuropsychological tests were combined into two cognitive composites -- one for language functions and the other for executive functions. There were 107 patients who underwent baseline assessment and 78 who completed a follow-up assessment within 10-16 months. Two global measures, the FTLD-modified Clinical Dementia Rating (FTLD-modified CDR) and the Clinical Global Impression of Change (CGIC) demonstrated decline in the majority of patients. Several cognitive measures showed negligible floor or ceiling scores either at baseline or follow-up. Scores declined at follow-up in the majority of patients. The cognitive, executive and combined composites were shown to be sensitive to change across all FTLD syndromes. Patients improved at follow-up on the behavioural scales -- the Frontal Behavioural Inventory (22%) and the Neuropsychiatric Inventory (28%) -- suggesting that these instruments may not be ideal for clinical trial use. It was feasible to recruit FTLD patients in a simulated multi-centre trial. There are several candidate outcome measures -- including the FTLD-CDR and the cognitive composites -- that could be used in clinical trials across the spectrum of FTLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Findings showed the FTLD-CDR demonstrated annual decline over years in genetic and sporadic FTD population (Knopman et al., 2008; Mioshi et al., 2017; Staffaroni et al., 2019a,b; Anderl-Straub et al., 2021; Lima-Silva et al., 2021).”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Knopman et al., 2008
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The adapted version of the CDR, FTLD-modified Clinical Dementia Rating scale (FTLD-CDR); (Knopman et al., 2008), added domains of language and behavior to the original scale, accounting for the most prominent symptoms in bvFTD (Knopman et al., 2011).”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Knopman et al., 2008
In the citing paper
“Overall, literature demonstrated these measures can detect functional decline in bvFTD over extensive follow-up time (1–7 years) (Knopman et al., 2008; Mioshi and Hodges, 2009; O’Connor et al., 2016; Staffaroni et al., 2019b; Giebel et al., 2021).”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Knopman et al., 2008
In the citing paper
“While one study did not report such behavioral inflection point during follow-up (Linds et al., 2015), the relative reduction of positive symptoms may show improvement of behavioral scores over time (Knopman et al., 2008).”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Knopman et al., 2008
In the citing paper
“However, given cognitive heterogeneity, combining multiple test scores into (executive functioning, language and memory) composites is known to increase sensitivity to change and ability to detect annual decline in bvFTD (Knopman et al., 2008).”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Knopman et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Validity of the Trail Making Test as an Indicator of Organic Brain Damage
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 7,928
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Self-citationKaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Research works printed but not linked: 3
- 2007, CLINICAL FEATURES OF PATHOLOGIC SUBTYPES OF BEHAVIORALVARIANT FRONTOTEMPORAL DEMENTIA ARCH NEUROL, 64, 1611
- 1997, Alzheimer disease and associated disorders, 11, 13S
- Sulestrowska, 1958, Medline Rows With NULL issns Will Point To This, 8, 271
Cited by
Frontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and Management
Rabinovici, G. D., & Miller, B. L. (2010) · CNS Drugs · doi:10.2165/11533100-000000000-00000 · Cited by 501
Self-citationBehavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management
Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70299-4 · Cited by 496
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I. O. C., Dick, K. M., Brotherhood, E., Gordon, E., Fellows, A., Toombs, J., Druyeh, R., Cardoso, M. J., Ourselin, S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 432
Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech
Josephs, K. A., Duffy, J. R., Strand, E. A., Machulda, M. M., Senjem, M. L., Master, A. V., Lowe, V. J., Jack, C. R., & Whitwell, J. L. (2012) · Brain · doi:10.1093/brain/aws032 · Cited by 419
Primary progressive aphasia: clinicopathological correlations
Grossman, M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.216 · Cited by 414
Metadata
- Authors
- Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N.
- Affiliations
- Mayo Clinic (US)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-21
- Volume
- 131
- Issue
- 11
- Pages
- 2957-2968
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2725027
- OpenAlex
- W1984148891
- Cited by
- 442
- References
- 48
- Citations by year
- 2026: 25 · 2025: 31 · 2024: 36 · 2023: 28 · 2022: 30 · 2021: 41 · 2020: 49 · 2019: 36 · 2018: 26 · 2017: 13 · 2016: 20 · 2015: 17 · 2014: 21 · 2013: 20 · 2012: 14
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30-AG-19610, P50‐AG16574, U01AG016976, P50AG016570, P30AG019610, R01AG023195, P01AG019724, P50AG023501, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- frontotemporal lobar degeneration, clinical trial design, outcome measures, disease progression, behavioral variant frontotemporal dementia, progressive nonfluent aphasia, semantic dementia, neuropsychological assessment, Clinical Global Impression of Change, Neuropsychiatric Inventory, floor and ceiling effects, language loss, executive function decline
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aphasia, Cognition Disorders, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Research Design, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. https://app.cochat.ai/papers/10.1093/brain/awn234
- The paper
- Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008). Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. https://doi.org/10.1093/brain/awn234
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.